LP-284, the synthetic enantiomer of acylfulvene compound
LP-184, has been identified as a highly effective agent against
hematologic cancers. It demonstrates superior antiproliferative effects compared to five other acylfulvenes, including its natural counterpart. The unique potency of LP-284 may stem from its distinct metabolic activation, transport mechanisms, or interactions with cellular components. Our study investigated the role of
Prostaglandin Reductase 1 (PTGR1), an enzyme that activates
Irofulven, in relation to the sensitivity of LP-284. We discovered a strong correlation between PTGR1 expression and the sensitivity to LP-184 and Irofulven, but not to LP-284. PTGR1 expression was notably lower in hematologic cancer cells, suggesting another activator for LP-284 in these cells.
A comprehensive analysis of 489 oxidoreductases revealed no significant correlation with LP-284 activity. LP-284 showed remarkable efficacy in cell viability assays across various hematologic cancer types, with particularly potent effects on
acute lymphocytic leukemia, chronic myeloid leukemia,
B-cell lymphoma, and
Multiple Myeloma (MM). The combination of LP-284 with
spironolactone, a
hypertension drug, was explored for its therapeutic potential in MM. Spironolactone degrades
ERCC3, a key component of the TC-NER pathway, which enhances the cytotoxicity of LP-284 by making cells more susceptible to DNA lesions.
The findings underscore the significance of stereochemistry in acylfulvene efficacy and highlight LP-284 as a promising candidate for treating hematologic cancers. The drug's potential to induce DNA damage that is lethal to cells with impaired DNA repair mechanisms and to inhibit transcription of essential fusion genes until repair is completed, positions LP-284 as a potential targeted therapy for
cancers with compromised DNA repair capabilities.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
